DT-Web

DB00522 - Bentiromide


Identification
Name Bentiromide
Accession Number DB00522 (APRD00818)
Type small molecule
Description Bentiromide is a peptide used as a screening test for exocrine pancreatic insufficiency and to monitor the adequacy of supplemental pancreatic therapy. It is given by mouth as a noninvasive test. The amount of 4-aminobenzoic acid and its metabolites excreted in the urine is taken as a measure of the chymotrypsin-secreting activity of the pancreas. Headache and gastrointestinal disturbances have been reported in patients taking bentiromide. Bentiromide is not available in the U.S. or Canada (It was withdrawn in the US in October 1996).
Structure
MOL SDF PDB SMILES InChI
Categories (*)
Molecular Weight 404.4153
Groups approved
Monoisotopic Weight 404.13722176
Pharmacology
Indication Used as a screening test for exocrine pancreatic insufficiency and to monitor the adequacy of supplemental pancreatic therapy.
Mechanism of action Bentiromide is a peptide that is broken down in the pancreas by chymotrypsin. By determining the output of unchanged bentiromide in the urine following oral administration, it is possible to determine the sufficiency of pancreatic activity.
Absorption Not Available
Protein binding Not Available
Biotransformation Primarily hepatic. Enzymatic activity capable of hydrolyzing bentiromide has also been found in normal small intestine.
Route of elimination Not Available
Toxicity Symptoms of overdose include shortness of breath and troubled breathing.
Affected organisms
  • Humans and other mammals
Interactions
Drug Interactions Not Available
Food Interactions Not Available

Targets


Serine protease hepsin
Name Serine protease hepsin
Gene Name HPN
Pharmacological action yes
Actions ligand
References
  • Chowdhury RS, Forsmark CE: Review article: Pancreatic function testing. Aliment Pharmacol Ther. 2003 Mar 15;17(6):733-50. - Pubmed
  • Bujanover Y, Harel A, Geter R, Blau H, Yahav J, Spirer Z: The development of the chymotryptic activity during postnatal life using the bentiromide test. Int J Pancreatol. 1988 Jan-Feb;3(1):53-8. - Pubmed
  • Toskes PP: The bentiromide test for pancreatic exocrine insufficiency. Pharmacotherapy. 1984 Mar-Apr;4(2):74-80. - Pubmed
  • Berman HM, Westbrook J, Feng Z, Gilliland G, Bhat TN, Weissig H, Shindyalov IN, Bourne PE: The Protein Data Bank. Nucleic Acids Res. 2000 Jan 1;28(1):235-42. - Pubmed
DTHybrid score 0.7727

Predictions


Id Partner name Gene Name Score
3176 Trypsin-1 PRSS1 0.1305
5212 Carboxylesterase 2 estB 0.073
5211 Extracellular subtilisin-like serine proteinase Not Available 0.0729
1334 Tissue factor pathway inhibitor TFPI 0.0682
3490 Sigma factor sigB regulation protein rsbQ rsbQ 0.0581
2139 Tissue factor F3 0.0561
1074 Urokinase-type plasminogen activator PLAU 0.0541
1615 Chymase CMA1 0.0528
2517 Subtilisin BPN' apr 0.0524
448 Vitamin K-dependent gamma-carboxylase GGCX 0.0444
369 Coagulation factor VII F7 0.0441
54 Prothrombin F2 0.0433
239 Coagulation factor X F10 0.0343
↑